Aravive, Inc.
Aravive, Inc. (ARAV): 1 pipeline candidate · ~3 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.7 months
D/E 6.67 · 3% dilution
Lead: Phase 3
1 candidate
N/A
N/A
A transparent, data-derived signal for Aravive, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$8.5M
Quarterly Burn
$9.8M
Runway
2.7 mo
Revenue
$2.8M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| batiraxcept | Phase 3 |
Frequently asked questions
How many drug candidates are in Aravive, Inc.'s pipeline?
Aravive, Inc. (ARAV) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Aravive, Inc.'s lead drug candidate?
Aravive, Inc.'s most advanced tracked candidate is batiraxcept (Phase 3) for Pancreatic ductal adenocarcinoma (PDAC).
What is Aravive, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Aravive, Inc. has approximately 2.7 months of cash runway.
Who is the CEO of Aravive, Inc.?
Gail Mc is the chief executive officer of Aravive, Inc. (ARAV).
Get the full picture on Aravive, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.